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Results: 
 
Does consideration of the FEF25-75 affect the association between SCD morbidity and lung 
function pattern? 
 
Given recent studies that have investigated whether measurement of the FEF25-75 offers 
additional information that could contribute to clinical decision making(1, 2), we examined the 
extent to which adding patients who were categorized in the “normal” group but had a reduced 
FEF25-75 to the “obstruction” group would change the associations between this lung function 
pattern and morbidity.  
We found 14 additional participants in the “normal” group who would have been 
reclassified as having obstruction (9% of the total cohort) using FEF25-75<LLN criteria in spite of 
having a normal FEV1/FVC ratio. (Of note, we also found 6 patients with a reduced FEV1/FVC 
ratio who had an FEF25-75 at or above the LLN).  Repeating our analyses of factors associated 
with baseline lung function showed that including FEF25-75<LLN criteria did not change the 
results – prior morbidity was not associated obstruction (Table E4). Similarly when we repeated 
our multivariable models examining the associations between lung function pattern and 
prospective morbidity, there were no associations between obstruction and future rates of pain or 
ACS (Table E4).   
 
 Table E1. Final negative binomial regression models for prospective rates of ACS and vaso-
occlusive pain in children with SCA who had at least 12 months of prospective follow-up 
(N=121) 
 IRR 95% CI P Value 
E2a. Prospective rates of ACS 
Retrospective rate of ACS events per year 18.98 8.92-70.35 <0.001 
Obstructive pattern 0.89 0.42-1.89 0.77 
Restrictive pattern 1.99 0.46-2.14 0.99 
Non-specific pattern 1.58 0.23-1.45 0.24 
E2b. Prospective rates of pain 
Age (years) 1.07 0.995-1.15 0.07 
Retrospective rate of pain events per year 2.21 1.72-2.84 <0.001 
Obstructive pattern 0.67 0.33-1.37 0.26 
Restrictive pattern 0.58 0.32-1.03 0.06 
Non-specific pattern 0.89 0.41-1.95 0.77 
 
 
  
Table E2. Final negative binomial regression models for prospective rates of ACS and vaso-
occlusive pain in children with SCA, including HU as a covariate (N=136) 
 IRR 95% CI P Value 
E3a. Prospective rates of ACS 
Taking HU 2.04 1.14-3.64 0.02 
Retrospective rate of ACS events per year 12.24 6.28-23.86 <0.001 
Obstructive pattern 0.86 0.42-1.76 0.67 
Restrictive pattern 1.12 0.53-2.37 0.78 
Non-specific pattern 0.50 0.19-1.30 0.15 
E3b. Prospective rates of pain 
Age (years) 1.07 1.01-1.14 0.022 
Taking HU 2.17 1.22-3.85 0.008 
Retrospective rate of pain events per year 2.08 1.67-2.58 <0.001 
Obstructive pattern 0.66 0.36-1.21 0.18 
Restrictive pattern 0.62 0.33-1.18 0.15 
Non-specific pattern 0.95 0.40-2.25 0.91 
 
  
 Table E3. Logistic regression models of the association between retrospective rates of ACS and 
pain and having obstruction (defined as FVC > LLN with FEV1/FVC <LLN or FEF25-75 < LLN; 
N=35 with obstruction versus 79 with normal lung function) 
 
 Model 1* Model 2† Model 3‡ Model 4§ 
 OR (95% CI) 
P Value 
OR (95% CI) 
P Value 
OR (95% CI) 
P Value) 
OR (95% CI) 
P Value 
Retrospective  
ACS Rate 
2.18 (0.49-9.74) 
0.31 
2.30 (0.48-10.97) 
0.29 
2.30 (0.47-11.22) 
0.39 
1.60 (0.28-9.12) 
0.60 
Retrospective  
Pain rate 
0.65 (0.30-1.43) 
0.29 
0.66 (0.30-1.45) 
0.30) 
0.69 (0.29-1.62) 
0.39 
0.84 (0.37-1.89) 
0.84 
* Unadjusted model 
† Model adjusted for age and gender 
‡ Model adjusted for age, gender, and SCD factors (hemoglobin [g/dL], white blood cell count, 
and reticulocyte %) 
§ Model adjusted for age, gender, and pulmonary factors of interest (has asthma, bronchodilator 
response >12%, early life ETS exposure, ln (IgE)) 
 
 
  
Table E4. Alternate* negative binomial regression models for prospective rates of ACS and 
vaso-occlusive pain in children with SCA, (N=136) 
 
 IRR 95% CI P Value 
E3a. Prospective rates of ACS 
Retrospective rate of ACS events per year 13.90 7.33-26.42 <0.001 
Obstruction pattern 1.07 0.56-2.04 0.85 
Restriction pattern 1.08 0.51-2.30 0.84 
Non-specific pattern 0.58 0.22-1.51 0.26 
Has BD response > 12% 1.48 0.85-2.59 0.17 
E3b. Prospective rates of pain 
Retrospective rate of pain events per year 2.29 0.80-2.90 <0.001 
Obstruction pattern 1.02 0.61-1.73 0.93 
Restriction pattern 0.66 0.37-1.15 0.14 
Non-specific pattern 1.08 0.55-2.12 0.82 
Age 1.06 0.99-1.13 0.10 
Hb (g/dL) 1.15 0.95-1.39 0.16 
WBC 1.06 0.99-1.13 0.12 
 
*Using alternate classification scheme in which the Obstruction pattern group includes those 
with either an FEV1/FVC ratio below the LLN or the FEF25-75 below the LLN 
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